Bryce Point Capital LLC Makes New $115,000 Investment in Dyne Therapeutics, Inc. $DYN

Bryce Point Capital LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 12,055 shares of the company’s stock, valued at approximately $115,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in DYN. CWM LLC grew its stake in Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after purchasing an additional 1,900 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after buying an additional 2,446 shares in the last quarter. Quarry LP purchased a new stake in shares of Dyne Therapeutics in the 1st quarter worth about $47,000. E Fund Management Co. Ltd. increased its stake in shares of Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock worth $144,000 after acquiring an additional 1,923 shares in the last quarter. Finally, Optimize Financial Inc purchased a new position in Dyne Therapeutics during the 1st quarter valued at about $154,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 10.7%

Shares of NASDAQ:DYN opened at $21.52 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $35.68. The company has a market cap of $3.06 billion, a P/E ratio of -5.58 and a beta of 1.09. The stock’s fifty day moving average price is $15.32 and its 200-day moving average price is $12.59.

Insider Activity

In other news, CEO John Cox sold 2,640 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the sale, the chief executive officer directly owned 199,539 shares in the company, valued at $2,675,817.99. The trade was a 1.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 14.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DYN. Chardan Capital decreased their target price on shares of Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, July 29th. Stifel Nicolaus reduced their price objective on Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Lifesci Capital raised Dyne Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Evercore ISI reissued an “outperform” rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Finally, Oppenheimer reaffirmed a “market perform” rating and issued a $13.00 price target on shares of Dyne Therapeutics in a research report on Friday, October 10th. Four analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $34.07.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.